According to
Clinical Trials Today, Pfizer plans to publicly report payments made to clinical investigators, physicians and other health care professionals by early next year, making it the first pharmaceutical company to commit to disclosing payments it makes for conducting clinical trials, speaking and consulting. It seems that Pfizer wants to aim for transparency of their practices, perhaps providing an easier system of due diligence within the pharmaceutical and CRO/Clinical Trials arenas. What do you think of this move by Pfizer?
No comments:
Post a Comment